SCHEMBL257374

SCHEMBL257374

Cc1cccc(C(=O)c2ccccc2)c1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 2/20 0.52
PDK1 Q15118 1/20 0.49
PDK2 Q15119 1/20 0.49
PDK3 Q15120 1/20 0.49
PDK4 Q16654 1/20 0.49
POLB P06746 1/20 0.49
NR4A1 P22736 1/20 0.49
MAPT P10636 2/20 0.48
GAA P10253 1/20 0.48
ALDH1A1 P00352 3/20 0.46
MYC P01106 2/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
KMT2A Q03164 1/20 0.46
ATM Q13315 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
NPSR1 Q6W5P4 1/20 0.44
KDM4E B2RXH2 1/20 0.44
HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7585613 0.87 NR4A1 (0.56) AKR1C3NR4A1MAPTALDH1A1CYP2C9
SCHEMBL28358891 0.87 AKR1C3 (0.56) AKR1C3NR4A1MAPTGAAALDH1A1
SCHEMBL23070440 0.86 KMT2A (0.48) AKR1C3POLBNR4A1ALDH1A1MYC
SCHEMBL4593813 0.85 AKR1C3 (0.47) AKR1C3PDK1PDK2PDK3PDK4
SCHEMBL256846 0.84 POLB (0.61) POLBMAPTKMT2AL3MBTL1NPSR1
SCHEMBL28579758 0.82 POLB (0.46) AKR1C3POLBALDH1A1CYP2C9L3MBTL1
SCHEMBL9451511 0.82 AKR1C3 (0.61) AKR1C3POLBMAPTGAAALDH1A1
SCHEMBL236 0.82 AKR1C3 (0.61) AKR1C3POLBMAPTGAAALDH1A1
SCHEMBL29402362 0.82 AKR1C3 (0.61) AKR1C3POLBMAPTGAAALDH1A1
Benzene SCHEMBL27600962 0.82 AKR1C3 (0.61) AKR1C3POLBMAPTGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115960483-A Method for reducing shrinkage stress of photocureable coating by using pH-responsive cationic microgel 江南大学 2023-04-14 CN disclosed
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
EP-2612848-A1 CYCLIC AMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2013-07-10 EP disclosed
WO-2012029942-A1 CYCLIC AMIDE DERIVATIVE 大日本住友製薬株式会社 (JP) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE HDAC10, H1-10, H1-0 AKR1C3 280/4885PDK1 2815/4885PDK2 2033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.